A phase 2 clinical trial (NCT00203892) aimed to validate the therapeutic potential of a modified CEA peptide in combination with GM-CSF in PDA patients who underwent chemo- and radiation therapy, HLA-A2+ and CEA-expressing. Here, CEACAM5 is linked to Patent ductus arteriosus.